



NASDAQ: AEMD

November 2020

FORWARD LOOKING STATEMENTS

The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier[®] and other product offerings; regulatory delays, manufacturing delays, delays in our clinical trials, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com

Aethlon Medical


- Hemopurifier[®] for oncology and viral diseases
- Experienced management team
- Strong cash position
- Non-dilutive NCI funding for multiple programs
- Exosome Sciences, Inc.
 - 80% owned subsidiary
 - Diagnostics for cancer and CTE / neurodegenerative disease
- Based in San Diego

The Aethlon Hemopurifier®



- Two FDA “Breakthrough Device” designations
 - Safety in over 120 patient treatments
 - Proprietary mechanism of action
 - Clears life-threatening glycosylated viruses
 - Clears cancer promoting exosomes

Hemopurifier[®] Design




- Hollow-fiber plasma separator filled with proprietary affinity resin in the extra-capillary space outside of cartridge fibers
- Captures enveloped viral pathogens and exosomes in circulating blood based on size and glycosylation



- Used with either dialysis or CRRT machine. Proprietary pump closed system being evaluated
- Capture of glycosylated particles contrasts with clearance of inflammatory mediators by other extracorporeal cartridges

Pipeline



Hemopurifier[®] Programs

Oncology


- Clearance of cancer promoting exosomes
- Potentially synergistic with chemotherapy, immunotherapy, targeted agents
- Multiple potential clinical targets
 - Breast, head and neck, gastrointestinal, melanoma, other solid tumors
- Well characterized markets, development pathways & endpoints
- Early feasibility study (EFS) in head and neck cancer being initiated

What are Exosomes?

- Extra-cellular particles shed from both normal and malignant cells
- Primary means of intra-cellular communication
- Tumor derived exosomes (TEX)—released by tumor cells that promote
 - metastasis, chemotherapy/targeted therapy resistance, immune suppression
- No existing treatment for depleting tumor-derived exosomes
- Also involved in viral disease – inflammation, coagulopathy
- Hemopurifier[®] may represent first candidate capable of clearing exosomes

Tumor-derived Exosomes (TEX)

Tumor-derived
exosomes



Cell membrane

Cytoplasm

250 nm

Exosomes being released by a tumor cell

National Cancer Institute Studies

- Phase I contract from NCI — Completed
 - “*Device Strategy for Differential Isolation of Oncosomes and Non-Malignant Exosomes*”

- Ongoing NCI SBIR Grant
 - “*The Hemopurifier[®] Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation*”

- Phase II NCI SBIR Contract — September 2019
 - \$1.8 million over 2 years
 - “*Technologies for Differential Isolation of Exosomes and Oncosomes*”

- NIDCR RO1 — July 2020
 - Collaboration with University of Pittsburgh, MGH, UHawaii
 - \$3.5 million over 5 years
 - “*Depleting exosomes to improve responses to immune therapy in head and neck squamous cell carcinoma*”

EFS in Head and Neck Carcinoma

- NCT #04453046
- University of Pittsburgh Hillman Cancer Center
- 10-12 subjects with advanced or metastatic HNSCC
- Combination with pembrolizumab (Keytruda[®])
 - Keytruda approved June 2019 in front line setting
- 4-hour Hemopurifier treatment immediately prior to Keytruda
- Endpoints: Safety, exosome clearance and characterization
 - ORR, PFS, OS
- IRB approved—start up in progress

Hemopurifier[®] Treatment of Viral Infections

- Demonstrated clearance of multiple different viruses *in vitro*
 - HIV, dengue, West Nile, influenza, Ebola, herpes, MERS
- Safety and viral clearance in four human clinical trials in HCV
- Over 120 successful applications in humans with HCV with no safety issues
- Single patient treatments in Ebola and HIV
 - Open protocol for emergency Use in US and Canada for Ebola
 - IDE Supplement for COVID-19 - June 2020

Hemopurifier[®] Treatment of SARS-CoV-2/COVID-19

- Circulating virus correlates with cytokine levels and poor outcome
- Hemopurifier has been shown to clear MERS, another coronavirus
- Clears SARS-CoV-2/COVID-19 glycoproteins
- IDE supplement for COVID-19 approved June 17, 2020
- New Feasibility Study starting
- Approved for 20 sites—40 patients in total
- ICU patients with severe or life-threatening symptoms and central IV access
- Patients already being treated under Single Patient Emergency Use regulations

Aethlon Leadership

Charles J. Fisher, Jr., M.D., FACP, FCCP, FCCM, Chief Executive Officer

- **Academic & Industry thought leader in sepsis & inflammation**
- **Head of critical care—Cleveland Clinic**
- **35 years industry development experience**
- **Senior executive—Lilly, Abbott, Cardiome**

James B. Frakes, Chief Financial Officer

- **29 years public company CFO experience**
- **Investment banking & venture capital**

Thomas L. Taccini, VP Manufacturing & Product Development

- **Over 35 years experience in engineering**
- **Product development and quality systems**

Strong Cash Position

- **June 30, 2020 Company's cash balance was approximately \$15.7 million**
- **No debt**
- **NASDAQ: AEMD ~12 million shares outstanding**

Upcoming News 2020-2021

Aethlon Hemopurifier®

- IDE supplement approved for SARS-CoV-2/COVID-19 ✓
- Emergency treatment of SARS-CoV-2/COVID-19 patients ✓
- EFS initiated for head and neck cancer
- Initiation of SARS-CoV-2 trial
- Early clinical data from EFS trials
- Proof of concept for other solid tumors

Summary

- **Unique Hemopurifier[®] blood purification device**
- **Two FDA Breakthrough Designations**
- **Multiple therapeutic targets in cancer and viral disease**
- **Management team with over 100 years healthcare experience**
- **Exosome Sciences subsidiary**
 - **Diagnostics in cancer and neurodegenerative disease**



9635 Granite Ridge Drive, Suite 100

San Diego, California 92123

858.459.7800

Nasdaq: AEMD

www.AethlonMedical.com

This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier[®] and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com